Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-<κ>O)benzamidato-<κ>O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">System and parameters</td><td class="align_center" colspan="2">PPARγ</td><td class="align_center" colspan="2">PPARγ + DBDF2,6T</td></tr><tr class="thead"><td class="align_left">Fluorescence peak</td><td class="align_center">Peak 1</td><td class="align_center">Peak 2</td><td class="align_center">Peak 1</td><td class="align_center">Peak 2</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Peak position (λex/λem nm/nm)</td><td class="align_center">283/337</td><td class="align_center">230/328</td><td class="align_center">290/340</td><td class="align_center">231/332</td></tr><tr><td class="align_left">Relative intensity (I)</td><td class="align_center">1275</td><td class="align_center">160</td><td class="align_center">1200</td><td class="align_center">150</td></tr><tr><td class="align_left">I1/I2</td><td class="align_center" colspan="2">7.97 : 1</td><td class="align_center" colspan="2">8.00 : 1</td></tr><tr><td class="align_left">Stokes shift (Δλ/nm)</td><td class="align_center">48</td><td class="align_center">107</td><td class="align_center">50</td><td class="align_center">109</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Several characteristic parameters of 3D fluorescence experiments.</div>

Bioinorganic Chemistry and Applications

tab4

Table 4

Table 4: Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-<κ>O)benzamidato-<κ>O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ

Table 4 | Exploration on the Interaction Ability of Antitumor Compound Bis-[2,6-difluoro-N-(hydroxyl-O)benzamidato-O]dibutylitin(IV) with Human Peroxisome Proliferator-Activated Receptor hPPARγ 